Myriad Genetics will present six abstracts at the 2026 ASCO Annual Meeting showcasing its Precise MRD assay’s prognostic power across diverse cancers, reporting 97% baseline ctDNA detection and 16% ultra-sensitive positivity. The company also plans multiple oncology test launches and GeneSight reimbursement gains to support its 2026 revenue guidance.
Myriad will present six posters and host an industry expert theater session at the 2026 ASCO Annual Meeting to highlight its Precise MRD test’s clinical utility across solid tumors including gastric, ovarian, head and neck cancers, and sarcoma.
Interim data from the MONSTAR-SCREEN-3 study report 97% baseline ctDNA detection with 16% of samples detected in the ultra-sensitive range, and show that patients with ctDNA positivity one month post-surgery experienced significantly worse disease-free survival.
Myriad plans multiple oncology assay launches throughout 2026, including its ultra-sensitive MRD test, and expects improved GeneSight reimbursement to bolster its revenue guidance and expand its cancer care offerings.
